Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §2

Mazdutide — pharmacology

Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.

Document identifier
CEI-MN-014/2
Series
Compound monograph
Version
3.1
Published
22 Feb 2025
Last reviewed
22 Jun 2026
Next review
22 Jun 2028
Identifier
10.71829/cei.mono.14
Certainty
Moderate
Cycle
2025 Q1

§2Pharmacology

§2.1Molecular targets

Table 2. Molecular targets recorded for Mazdutide, with the character of the interaction and the potency where the Institute holds it.

TargetInteractionNote
GLP-1 receptor (GLP1R)AgonistDominant arm
Glucagon receptor (GCGR)AgonistLower relative potency than the GLP-1 arm

§2.2Mechanism of action

Mazdutide reproduces the natural dual activity of oxyntomodulin with a pharmacokinetic profile suitable for weekly dosing. The glucagon arm contributes energy expenditure and hepatic lipid mobilisation; the GLP-1 arm supplies appetite suppression and glycaemic control.[1,2]

§2.3Pharmacokinetics

Terminal half-life
≈5–6 days
Time to maximum concentration
approximately 24–36 h
Volume of distribution
not published
Plasma protein binding
high
Clearance
not published
Bioavailability
not published

Assumed proteolytic with beta-oxidation.

Reconstructed plasma concentration–time profilePlasma concentration plotted against time after dosing, reconstructed from published pharmacokinetic parameters.0.00.51.01.50200400600800Time after first dose (hours)Relative concentrationt max ≈ 551 ht½ ≈ 144 h
Modelled profileSimulated observationsDose administration
Figure 2. Illustrative. Plasma concentration–time profile reconstructed by the Institute from the published half-life and time-to-maximum-concentration parameters using a one-compartment model with first-order absorption. The curve is not digitised from a published figure and its vertical scale is relative. It is published to convey the shape of the profile and the approach to steady state, not to supply a concentration at any time point.

§2.4Interactions

  • Not fully characterised

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Ji L, Jiang H, Bi Y, Li X, Ning G, Qu S, Wu Y, Yang J, Chen L, Li L, Zhang M, Qian L. Efficacy and safety of mazdutide in Chinese participants with overweight or obesity: a randomised, double-blind, placebo-controlled phase 2 trial. Diabetes, Obesity and Metabolism 2023;25(12):3691–3700. doi:10.1111/dom.15264
  2. Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 2019;30:72–130. doi:10.1016/j.molmet.2019.09.010 · PMID 31767182

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.